OnDosis
Jan Hellberg has a diverse work experience in various engineering roles. Most recently, they worked as a Senior Design Engineer at OnDosis since March 2021. Prior to that, they were a Design Engineer at Brigo from April 2019 to April 2020. Jan also served as a Design Engineer at Gothenburg medtech innovations AB, Cognibotics AB, and Bluetest AB in 2019, where they worked on projects related to medical devices, robot kinematics, and RF test chambers, respectively. Before that, they were a Lead Project Engineer at Polestar from October 2017 to March 2019, where they played a key role in the industrialization phase of the Polestar 1 project. Jan also worked as a Design Engineer at Escenda Engineering AB from September 2015 to March 2019, and as a System Engineer at CEVT (China Euro Vehicle Technology AB) from February 2017 to September 2017. Additionally, they were a Design Engineer at Polestar in 2016, focusing on the production of the "2018 aero package" in carbon fiber. Jan began their career at Volvo Cars as an Engineering/Concept Development Lead, where they led a project for the design of a collapsible front radar and grill proposal.
Jan Hellberg attended Aschebergsgymnasiet from 1983 to 1984, where they obtained a degree in Mechanical Engineering as a technical college graduate.
OnDosis
1 followers
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.